Compare IPCA Labs with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs ALEMBIC LTD - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS ALEMBIC LTD IPCA LABS/
ALEMBIC LTD
 
P/E (TTM) x 23.1 70.5 32.8% View Chart
P/BV x 4.5 2.5 179.1% View Chart
Dividend Yield % 0.1 0.4 25.7%  

Financials

 IPCA LABS   ALEMBIC LTD
EQUITY SHARE DATA
    IPCA LABS
Mar-18
ALEMBIC LTD
Mar-18
IPCA LABS/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs69572 965.8%   
Low Rs40034 1,179.9%   
Sales per share (Unadj.) Rs260.24.7 5,535.2%  
Earnings per share (Unadj.) Rs19.06.1 310.8%  
Cash flow per share (Unadj.) Rs33.16.2 529.3%  
Dividends per share (Unadj.) Rs1.000.20 500.0%  
Dividend yield (eoy) %0.20.4 48.3%  
Book value per share (Unadj.) Rs213.040.7 523.9%  
Shares outstanding (eoy) m126.20267.03 47.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.111.3 18.7%   
Avg P/E ratio x28.98.7 332.8%  
P/CF ratio (eoy) x16.68.5 195.4%  
Price / Book Value ratio x2.61.3 197.4%  
Dividend payout %5.33.3 160.9%   
Avg Mkt Cap Rs m69,12014,139 488.9%   
No. of employees `00013.3NA-   
Total wages/salary Rs m7,359207 3,548.1%   
Avg. sales/employee Rs Th2,477.4NM-  
Avg. wages/employee Rs Th555.2NM-  
Avg. net profit/employee Rs Th180.6NM-  
INCOME DATA
Net Sales Rs m32,8361,255 2,616.0%  
Other income Rs m418370 112.9%   
Total revenues Rs m33,2541,625 2,045.9%   
Gross profit Rs m4,505111 4,054.7%  
Depreciation Rs m1,77738 4,701.9%   
Interest Rs m2402 14,129.4%   
Profit before tax Rs m2,905442 657.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m51124 2,134.0%   
Profit after tax Rs m2,3941,630 146.9%  
Gross profit margin %13.78.9 155.0%  
Effective tax rate %17.65.4 324.5%   
Net profit margin %7.3129.8 5.6%  
BALANCE SHEET DATA
Current assets Rs m19,4551,867 1,042.0%   
Current liabilities Rs m10,076591 1,704.3%   
Net working cap to sales %28.6101.6 28.1%  
Current ratio x1.93.2 61.1%  
Inventory Days Days9894 103.9%  
Debtors Days Days6774 91.0%  
Net fixed assets Rs m20,2601,791 1,131.3%   
Share capital Rs m252534 47.3%   
"Free" reserves Rs m26,63310,324 258.0%   
Net worth Rs m26,88610,858 247.6%   
Long term debt Rs m2,34041 5,679.9%   
Total assets Rs m41,17311,591 355.2%  
Interest coverage x13.1260.9 5.0%   
Debt to equity ratio x0.10 2,293.8%  
Sales to assets ratio x0.80.1 736.4%   
Return on assets %6.414.1 45.5%  
Return on equity %8.915.0 59.3%  
Return on capital %10.815.2 70.9%  
Exports to sales %47.61.5 3,082.2%   
Imports to sales %14.921.0 70.9%   
Exports (fob) Rs m15,64219 80,629.4%   
Imports (cif) Rs m4,884263 1,854.5%   
Fx inflow Rs m15,64219 80,629.4%   
Fx outflow Rs m4,884264 1,851.1%   
Net fx Rs m10,759-244 -4,401.6%   
CASH FLOW
From Operations Rs m3,411236 1,446.7%  
From Investments Rs m-1,354-224 604.5%  
From Financial Activity Rs m-1,304-27 4,902.6%  
Net Cashflow Rs m753-15 -5,089.2%  

Share Holding

Indian Promoters % 45.9 64.0 71.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 0.2 5,700.0%  
FIIs % 25.3 9.7 260.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 26.1 66.7%  
Shareholders   36,892 54,701 67.4%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   GSK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  STERLING BIOTECH  JUBILANT LIFE SCIENCES  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Lower; Metal and Banking Stocks Drag(09:30 am)

Asian share markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 1% while the Hang Seng is up 1.1%.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Sep 19, 2019 11:37 AM

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS